ストックスクリーナーアプリを入手
0.0004
14.29%
0.000050
前日終値:
$0.00035
開ける：
$0.0002
24時間の取引高:
1,401
Relative Volume:
0.18
時価総額：
$N/A
収益：
$386.00K
当期純損益:
$-97.82M
株価収益率:
-0.000132
EPS:
-3.0311
ネットキャッシュフロー:
$-100.06M
1週間 パフォーマンス:
+14.29%
1か月 パフォーマンス:
-20.00%
6か月 パフォーマンス:
-92.00%
1年 パフォーマンス:
-99.50%
1日の値動き範囲:
$0.0002
$0.00045
1週間の範囲:
$0.0002
$0.00045
52週間の値動き範囲:
$0.0002
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Compare SYRS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0004 | 0 | 386.00K | -97.82M | -100.06M | -3.0311 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-11-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-08 | 再開されました | JMP Securities | Mkt Outperform |
| 2019-02-14 | 再開されました | Oppenheimer | Outperform |
| 2018-11-05 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-03-13 | 繰り返されました | Wedbush | Outperform |
| 2017-10-31 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-23 | 開始されました | ROTH Capital | Neutral |
| 2017-08-10 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
すべてを表示
Syros Pharmaceuticals Inc (SYRS) 最新ニュース
hVIVO plc (OPORF) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Syros Pharmaceuticals, Inc. (0LC7.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Stock List: Research Stocks from Around the World - GuruFocus
Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
MSN - MSN
MSN Money - MSN
Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
Reviewing Vectura Group (OTCMKTS:VEGPF) and Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Head-To-Head Review: Aerovate Therapeutics (NASDAQ:AVTE) vs. Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros to delist from Nasdaq, deregister from SEC - MSN
SYRS (Syros Pharmaceuticals) Price-to-Tangible-Book : (As of Oct. 22, 2025) - GuruFocus
CapEx per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Net current asset value per share of Syros Pharmaceuticals, Inc. – OTC:SYRS - TradingView
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Syros Pharmaceuticals, Inc. (SYRS) stock price, news, quote and history - Yahoo Finance Singapore
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - Yahoo Finance
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS Stock Price, News & Analysis - Stock Titan
Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals to Advance ADPKD Program - BioPharma APAC
Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Odyssey hires Jason Haas as CFO - BioCentury
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals announces major company changes - Investing.com
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - gurufocus.com
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
Syros stock dives 92% on failed Phase 3 study, possible loan default (NASDAQ:SYRS) - Seeking Alpha
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - Business Wire
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - The Malaysian Reserve
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
3.83%
大文字化:
|
ボリューム (24 時間):